Brazil Gives Musk’s xAI 30 Days to Tackle Fake Sexualized Content From Grok

/in /tarafından

Brazilian authorities have given xAI, founded by Elon Musk, 30 days to prevent its Grok chatbot from generating and circulating fake sexualized content, warning of further legal action if the company fails to comply.

In a joint statement, Brazil’s consumer protection agency Senacon, data protection authority ANPD, and the Office of Federal Prosecutors said xAI must introduce technical measures to identify, review, and remove inappropriate content created by Grok. Authorities also demanded the removal of accounts linked to the production of such material within the same timeframe.

The move follows concerns that Grok has continued to generate hyper-realistic sexualized imagery, sometimes described as deepfakes. While xAI has previously restricted image editing features and rolled back public posting of such imagery on the X platform, a Reuters test showed that the chatbot could still privately generate the content on request.

Brazilian officials said they may pursue administrative or judicial measures if the company does not meet the deadline. The action forms part of a broader global crackdown, as governments and regulators increase scrutiny of AI-generated sexual content, launching probes, imposing bans, and demanding stronger safeguards to prevent the spread of illegal material.

The case highlights mounting pressure on AI developers to balance innovation with effective content moderation as increasingly powerful generative tools enter public use.

SkyBridge Bets on Rising Volatility, Cautiously Optimistic on Bitcoin, Scaramucci Says

/in /tarafından

Alternative asset manager SkyBridge Capital is increasing its exposure to macro strategies as policy uncertainty under U.S. President Donald Trump fuels market volatility, founder Anthony Scaramucci said in Davos.

Scaramucci said macro-focused traders have performed better amid sharp market swings, prompting SkyBridge to tilt further toward such strategies. Regulatory filings from September 2025 showed the firm’s SkyBridge Opportunity Fund increased its macro weighting to 69%, compared with a heavier allocation to cryptocurrencies earlier in the year.

Despite recent turbulence, Scaramucci said the long-term outlook for Bitcoin remains intact. He described the recent pullback as a timing issue rather than a shift in direction, pointing to consolidation following a volatile year. Bitcoin surged to a record above $126,000 in October 2025 before a sharp correction that triggered more than $19 billion in liquidations, the largest in crypto history.

Bitcoin was trading below $90,000 on Tuesday, about 28% below its peak. Scaramucci said optimism around regulatory reform had faded but remained cautiously positive on the year ahead, noting that legislation to clarify crypto market rules is still under consideration in the U.S. Congress.

Bristol Myers Partners With Microsoft for AI-Driven Lung Cancer Detection

/in /tarafından

Bristol Myers Squibb has signed a partnership with Microsoft to use artificial intelligence-powered radiology tools to speed up the early detection of lung cancer, the companies said on Tuesday.

Under the agreement, Bristol Myers will deploy U.S. Food and Drug Administration-cleared radiology AI algorithms through Microsoft’s Precision Imaging Network. The platform analyzes X-ray and CT scan images to help clinicians identify lung disease and is already used by hospitals across the United States.

The companies said the AI tools could help doctors detect hard-to-spot lung nodules and identify patients at earlier stages of disease, when treatment options are more effective. A key objective of the collaboration is to expand access to early lung cancer detection in medically underserved areas, including rural hospitals and community clinics.

Alexandra Goncalves, vice president and head of digital health at Bristol Myers Squibb, said the partnership combines Microsoft’s scalable imaging technology with Bristol Myers’ oncology expertise to create an AI-enabled workflow that supports faster and more accurate diagnosis of non-small cell lung cancer and guides patients toward appropriate care pathways.

Pharmaceutical companies are increasingly adopting AI to improve efficiency across research, development, and clinical workflows. The collaboration reflects a broader industry push to apply AI not only to drug discovery but also to diagnostics and patient care, particularly in oncology.